Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E L Mayer

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030H A Parsons, T Blewett, X Chu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030H A Parsons, T Blewett, X Chu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
Pageof 4